- Home
- ONCY vs BOLD Comparison
ONCY vs BOLD Comparison
Compare ONCY & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- BOLD
- Stock Information
- Founded
- ONCY 1998
- BOLD 2018
- Country
- ONCY Canada
- BOLD United States
- Employees
- ONCY N/A
- BOLD N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- BOLD
- Sector
- ONCY Health Care
- BOLD
- Exchange
- ONCY Nasdaq
- BOLD Nasdaq
- Market Cap
- ONCY 53.6M
- BOLD 49.5M
- IPO Year
- ONCY 1999
- BOLD 2024
- Fundamental
- Price
- ONCY $0.56
- BOLD $1.51
- Analyst Decision
- ONCY Strong Buy
- BOLD Buy
- Analyst Count
- ONCY 4
- BOLD 3
- Target Price
- ONCY $4.00
- BOLD $22.50
- AVG Volume (30 Days)
- ONCY 224.8K
- BOLD 82.4K
- Earning Date
- ONCY 03-07-2025
- BOLD 03-27-2025
- Dividend Yield
- ONCY N/A
- BOLD N/A
- EPS Growth
- ONCY N/A
- BOLD N/A
- EPS
- ONCY N/A
- BOLD N/A
- Revenue
- ONCY N/A
- BOLD N/A
- Revenue This Year
- ONCY N/A
- BOLD N/A
- Revenue Next Year
- ONCY N/A
- BOLD N/A
- P/E Ratio
- ONCY N/A
- BOLD N/A
- Revenue Growth
- ONCY N/A
- BOLD N/A
- 52 Week Low
- ONCY $0.55
- BOLD $1.42
- 52 Week High
- ONCY $1.53
- BOLD $14.72
- Technical
- Relative Strength Index (RSI)
- ONCY 27.91
- BOLD N/A
- Support Level
- ONCY $0.58
- BOLD N/A
- Resistance Level
- ONCY $0.65
- BOLD N/A
- Average True Range (ATR)
- ONCY 0.03
- BOLD 0.00
- MACD
- ONCY -0.00
- BOLD 0.00
- Stochastic Oscillator
- ONCY 1.34
- BOLD 0.00
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.